Co-Diagnostics, Inc. to Host Sales space at Medlab Africa 2023 in Johannesburg, South Africa

SALT LAKE CITY, Oct. 16, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Firm” or “Co-Dx”), a molecular diagnostics firm with a novel, patented platform for the event of molecular diagnostic checks, introduced at the moment that the Firm will likely be internet hosting a sales space this week at Africa Well being/Medlab Africa in Johannesburg, South Africa on October 17-19, 2023.

The convention is described as the most important gathering of healthcare corporations, expertise, services within the sub-Saharan area, catering to an viewers of pros from the South African Growth Neighborhood area and world wide, together with distributors, authorities representatives, laboratory executives, and buying/procurement managers, who attend to fulfill with world-class suppliers and producers.

Co-Dx believes that the commerce present will contribute worthwhile perception into markets which can be anticipated to play an necessary position within the Firm’s future because it prepares to launch its upcoming Co-Dx PCR House™ platform.

Along with a take a look at for COVID-19, which is presently present process scientific evaluations on the platform in preparation for a submission to the FDA, Co-Dx has a number of different infectious illness checks in various levels of growth. Considered one of these checks is for tuberculosis (TB), a illness for which the World Well being Group estimates 25% of recent instances and deaths globally are discovered within the African area. Nigeria and South Africa are two of the 7 nations which have been estimated to account for over two thirds of world TB instances.

Co-Dx just lately introduced that it had acquired funding help from the Invoice & Melinda Gates Basis for use in direction of completion of the TB take a look at on the brand new Co-Dx PCR House platform.

Extra details about the convention may be discovered right here. Attendees considering studying extra concerning the Firm are invited to go to Sales space #2.C13.

The Co-Dx PCR House platform is topic to FDA overview and isn’t obtainable on the market.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah company, is a molecular diagnostics firm that develops, manufactures and markets state-of-the-art diagnostics applied sciences. The Firm’s applied sciences are utilized for checks which can be designed utilizing the detection and/or evaluation of nucleic acid molecules (DNA or RNA). The Firm additionally makes use of its proprietary expertise to design particular checks for its Co-Dx PCR House™ platform and to find genetic markers to be used in purposes apart from infectious illness.

Ahead-Trying Statements:
This press launch comprises forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995 (PSLRA) which can be topic to plenty of dangers and uncertainties. Ahead-looking statements may be recognized by phrases similar to “believes,” “expects,” “estimates,” “intends,” “could,” “plans,” “will” and comparable expressions, or the destructive of those phrases. Such forward-looking statements are primarily based on info and situations as they exist on the time such statements are made and predictions as to future info and situations. Ahead-looking statements on this launch embrace statements relating to our perception that our new platform will assist help the worldwide effort to assist stop the unfold of each TB and HPV and our consider that our new platform has the potential to dramatically enhance entry to diagnostics and cut back healthcare prices. Precise outcomes could differ materially from these contemplated or anticipated by such forward-looking statements. Readers of this press launch are cautioned to not place undue reliance on any forward-looking statements. There may be no assurance that any of the anticipated outcomes will happen on a well timed foundation or in any respect resulting from sure dangers and uncertainties, a dialogue of which may be present in our Threat Components disclosure in our Annual Report on Type 10-Ok, filed with the Securities and Alternate Fee (SEC) on March 16, 2023, and in our different filings with the SEC. The Firm doesn’t undertake any obligation to replace any forward-looking assertion regarding issues mentioned on this press launch, besides as could also be required by relevant securities legal guidelines.

SOURCE Co-Diagnostics